Eric Charpentier

Eric Charpentier

UNVERIFIED PROFILE

Are you Eric Charpentier?   Register this Author

Register author
Eric Charpentier

Eric Charpentier

Publications by authors named "Eric Charpentier"

Are you Eric Charpentier?   Register this Author

17Publications

1159Reads

46Profile Views

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.

Blood Cancer J 2019 03 29;9(4):41. Epub 2019 Mar 29.

City of Hope Cancer Center and International Myeloma Foundation, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-019-0198-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440961PMC
March 2019

An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8 T cells involved in multiple sclerosis.

J Autoimmun 2018 03 18;88:61-74. Epub 2017 Oct 18.

Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; Service de Neurologie, CHU Nantes, Nantes, France; INSERM 015, Centre d'Investigation Clinique, Nantes, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaut.2017.10.005DOI Listing
March 2018

De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability.

Authors:
Sébastien Küry Geeske M van Woerden Thomas Besnard Martina Proietti Onori Xénia Latypova Meghan C Towne Megan T Cho Trine E Prescott Melissa A Ploeg Stephan Sanders Holly A F Stessman Aurora Pujol Ben Distel Laurie A Robak Jonathan A Bernstein Anne-Sophie Denommé-Pichon Gaëtan Lesca Elizabeth A Sellars Jonathan Berg Wilfrid Carré Øyvind Løvold Busk Bregje W M van Bon Jeff L Waugh Matthew Deardorff George E Hoganson Katherine B Bosanko Diana S Johnson Tabib Dabir Øystein Lunde Holla Ajoy Sarkar Kristian Tveten Julitta de Bellescize Geir J Braathen Paulien A Terhal Dorothy K Grange Arie van Haeringen Christina Lam Ghayda Mirzaa Jennifer Burton Elizabeth J Bhoj Jessica Douglas Avni B Santani Addie I Nesbitt Katherine L Helbig Marisa V Andrews Amber Begtrup Sha Tang Koen L I van Gassen Jane Juusola Kimberly Foss Gregory M Enns Ute Moog Katrin Hinderhofer Nagarajan Paramasivam Sharyn Lincoln Brandon H Kusako Pierre Lindenbaum Eric Charpentier Catherine B Nowak Elouan Cherot Thomas Simonet Claudia A L Ruivenkamp Sihoun Hahn Catherine A Brownstein Fan Xia Sébastien Schmitt Wallid Deb Dominique Bonneau Mathilde Nizon Delphine Quinquis Jamel Chelly Gabrielle Rudolf Damien Sanlaville Philippe Parent Brigitte Gilbert-Dussardier Annick Toutain Vernon R Sutton Jenny Thies Lisenka E L M Peart-Vissers Pierre Boisseau Marie Vincent Andreas M Grabrucker Christèle Dubourg Wen-Hann Tan Nienke E Verbeek Martin Granzow Gijs W E Santen Jay Shendure Bertrand Isidor Laurent Pasquier Richard Redon Yaping Yang Matthew W State Tjitske Kleefstra Benjamin Cogné Slavé Petrovski Kyle Retterer Evan E Eichler Jill A Rosenfeld Pankaj B Agrawal Stéphane Bézieau Sylvie Odent Ype Elgersma Sandra Mercier

Am J Hum Genet 2017 Nov;101(5):768-788

CHU Nantes, Service de Génétique Médicale, 9 quai Moncousu, 44093 Nantes Cedex 1, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajhg.2017.10.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673671PMC
November 2017

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Blood 2017 06 8;129(25):3294-3303. Epub 2017 May 8.

Section of Bone Marrow Transplantation & Leukemia, Division of Oncology, Department of Medicine, Washington University, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-09-740787DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482100PMC
June 2017

Targeted resequencing identifies TRPM4 as a major gene predisposing to progressive familial heart block type I.

Int J Cardiol 2016 Mar 11;207:349-58. Epub 2016 Jan 11.

Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1087, l'institut du thorax, Nantes, France; Centre National de la Recherche Scientifique (CNRS) UMR 6291, l'institut du thorax, Nantes, France; Université de Nantes, l'institut du thorax, Nantes, France; Centre Hospitalier Universitaire (CHU) de Nantes, l'institut du thorax, Service de Cardiologie, Nantes, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2016.01.052DOI Listing
March 2016

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Int J Gynecol Cancer 2016 Feb;26(2):255-60

Departments of *Medicine and †Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY; ‡Sanofi Statistics Department, Cambridge MA; and §Department of Radiology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009457PMC
February 2016

Fine-scale human genetic structure in Western France.

Eur J Hum Genet 2015 Jun 3;23(6):831-6. Epub 2014 Sep 3.

1] INSERM UMR 1087, Nantes, France [2] CNRS, UMR 6291 institut du thorax, Nantes, France [3] Université de Nantes, Nantes, France [4] CHU Nantes, l'institut du thorax, Service de Cardiologie, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ejhg.2014.175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795055PMC
June 2015

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

J Clin Oncol 2014 Dec 27;32(34):3840-7. Epub 2014 Oct 27.

Joyce O'Shaughnessy, Baylor Charles A. Sammons Cancer Center, Texas Oncology; Joyce O'Shaughnessy, US Oncology, Dallas; Beth Hellerstedt Texas Oncology-Round Rock, Austin, TX; Lee Schwartzberg, Accelerated Community Oncology Research Network; Lee Schwartzberg, The West Clinic, Memphis; Denise A. Yardley, Sarah Cannon Research Institute; Denise A. Yardley, Tennessee Oncology, Nashville, TN; Michael A. Danso, US Oncology; Michael A. Danso, Virginia Oncology Associates, Norfolk; Nicholas Robert, Virginia Cancer Specialists, Fairfax; Paul Richards, Blue Ridge Cancer Care, Salem, VA; Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Hope S. Rugo, University of California, San Francisco Comprehensive Cancer Center, San Francisco; Robert W. Carlson, Stanford Comprehensive Cancer Center, Palo Alto, CA; Richard S. Finn, Geffen School of Medicine at University of California, Los Angeles; Richard S. Finn, Translational Research in Oncology, Los Angeles, CA; Marcus Neubauer, Kansas City Cancer City, Overland Park, KS; Mansoor Saleh, Georgia Cancer Specialists, Sandy Springs, GA; Jennifer M. Specht, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Eric Charpentier, Ignacio Garcia-Ribas, Sanofi, Cambridge; and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.55.2984
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.55.2984DOI Listing
December 2014

Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.

Nat Genet 2013 Sep 21;45(9):1044-9. Epub 2013 Jul 21.

Department of Clinical and Experimental Cardiology, Heart Failure Research Center, Academic Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869788PMC
September 2013